Inovio’s COVID-19 vaccine candidate shows promise in early-stage trial

(Reuters) – Inovio Pharmaceuticals Inc said on Tuesday its experimental coronavirus vaccine induced immune responses in healthy volunteers and was shown to be safe in an early-stage trial.

Based on preliminary data, the drug developer said 34 of the 36 volunteers showed overall immunological response rates and most of the side-effects were redness at the site of the shot.

Inovio said the vaccine would undergo trials in a separate study as part of the Trump administration’s “Operation Warp Speed” program.

Inovio’s vaccine is among the dozens of candidates being tested in human trial against the coronavirus.

(Reporting by Trisha Roy and Manas Mishra in Bengaluru; Editing by Arun Koyyur)